Gilead and Kite Advance Blood Cancer Treatment with Promising Cell Therapy Data at ASH 2025
At the 67th American Society of Hematology (ASH) Annual Meeting, Gilead Sciences and its subsidiary Kite showcased a suite of new data underscoring major progress in cell therapy for blood…